Pharmacological Characteristics and Efficacy of a Novel Anti-angiogenic Antibody FD006 in Corneal Neovascularization

Wang Q, et al., 14:17, BMC Biotechnol, 2014

The authors examined the pharmacological characteristics and efficacy of FD006, a novel anti-vascular endothelial growth factor (VEGF) that can regulate physiologic and pathologic angiogenesis specifically acting to inhibit corneal neovascularization. The studies demonstrate that FD006 has a higher affinity and better anti-neovascularization function than the well-known VEGF inhibitor becvacizumab/Avastin suggesting that it may be a promising agent in the treatment of corneal neovascularization in the near future. The binding kinetics of FD006 and bevacizumab to VEGF were performed on the Octet RED system, using Anti-Human IgG biosensors.

Read More